Numerical model of full-cardiac cycle hemodynamics in a total artificial heart and the effect of its size on platelet activation

Gil Marom, Wei Che Chiu, Jessica R. Crosby, Katrina J. DeCook, Saurabh Prabhakar, Marc Horner, Marvin J Slepian, Danny Bluestein

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The SynCardia total artificial heart (TAH) is the only Food and Drug Administration (FDA) approved device for replacing hearts in patients with congestive heart failure. It pumps blood via pneumatically driven diaphragms and controls the flow with mechanical valves. While it has been successfully implanted in more than 1300 patients, its size precludes implantation in smaller patients. This study’s aim was to evaluate the viability of scaled-down TAHs by quantifying thrombogenic potentials from flow patterns. Simulations of systole were first conducted with stationary valves, followed by an advanced full-cardiac cycle model with moving valves. All the models included deforming diaphragms and platelet suspension in the blood flow. Flow stress accumulations were computed for the platelet trajectories and thrombogenic potentials were assessed. The simulations successfully captured complex flow patterns during various phases of the cardiac cycle. Increased stress accumulations, but within the safety margin of acceptable thrombogenicity, were found in smaller TAHs, indicating that they are clinically viable.

Original languageEnglish (US)
Pages (from-to)788-796
Number of pages9
JournalJournal of Cardiovascular Translational Research
Volume7
Issue number9
DOIs
StatePublished - Nov 25 2014

Fingerprint

Artificial Heart
Platelet Activation
Hemodynamics
Diaphragm
Blood Platelets
Systole
United States Food and Drug Administration
Suspensions
Heart Failure
Safety
Equipment and Supplies

Keywords

  • Computational fluid dynamics
  • Fluid–structure interaction
  • Mechanical circulatory support devices
  • Thrombogenic potential
  • Total artificial heart

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Genetics
  • Genetics(clinical)
  • Molecular Medicine
  • Pharmaceutical Science

Cite this

Numerical model of full-cardiac cycle hemodynamics in a total artificial heart and the effect of its size on platelet activation. / Marom, Gil; Chiu, Wei Che; Crosby, Jessica R.; DeCook, Katrina J.; Prabhakar, Saurabh; Horner, Marc; Slepian, Marvin J; Bluestein, Danny.

In: Journal of Cardiovascular Translational Research, Vol. 7, No. 9, 25.11.2014, p. 788-796.

Research output: Contribution to journalArticle

Marom, Gil ; Chiu, Wei Che ; Crosby, Jessica R. ; DeCook, Katrina J. ; Prabhakar, Saurabh ; Horner, Marc ; Slepian, Marvin J ; Bluestein, Danny. / Numerical model of full-cardiac cycle hemodynamics in a total artificial heart and the effect of its size on platelet activation. In: Journal of Cardiovascular Translational Research. 2014 ; Vol. 7, No. 9. pp. 788-796.
@article{a312dfc1f54c47f69f17809240a24a0e,
title = "Numerical model of full-cardiac cycle hemodynamics in a total artificial heart and the effect of its size on platelet activation",
abstract = "The SynCardia total artificial heart (TAH) is the only Food and Drug Administration (FDA) approved device for replacing hearts in patients with congestive heart failure. It pumps blood via pneumatically driven diaphragms and controls the flow with mechanical valves. While it has been successfully implanted in more than 1300 patients, its size precludes implantation in smaller patients. This study’s aim was to evaluate the viability of scaled-down TAHs by quantifying thrombogenic potentials from flow patterns. Simulations of systole were first conducted with stationary valves, followed by an advanced full-cardiac cycle model with moving valves. All the models included deforming diaphragms and platelet suspension in the blood flow. Flow stress accumulations were computed for the platelet trajectories and thrombogenic potentials were assessed. The simulations successfully captured complex flow patterns during various phases of the cardiac cycle. Increased stress accumulations, but within the safety margin of acceptable thrombogenicity, were found in smaller TAHs, indicating that they are clinically viable.",
keywords = "Computational fluid dynamics, Fluid–structure interaction, Mechanical circulatory support devices, Thrombogenic potential, Total artificial heart",
author = "Gil Marom and Chiu, {Wei Che} and Crosby, {Jessica R.} and DeCook, {Katrina J.} and Saurabh Prabhakar and Marc Horner and Slepian, {Marvin J} and Danny Bluestein",
year = "2014",
month = "11",
day = "25",
doi = "10.1007/s12265-014-9596-y",
language = "English (US)",
volume = "7",
pages = "788--796",
journal = "Journal of Cardiovascular Translational Research",
issn = "1937-5387",
publisher = "Springer New York",
number = "9",

}

TY - JOUR

T1 - Numerical model of full-cardiac cycle hemodynamics in a total artificial heart and the effect of its size on platelet activation

AU - Marom, Gil

AU - Chiu, Wei Che

AU - Crosby, Jessica R.

AU - DeCook, Katrina J.

AU - Prabhakar, Saurabh

AU - Horner, Marc

AU - Slepian, Marvin J

AU - Bluestein, Danny

PY - 2014/11/25

Y1 - 2014/11/25

N2 - The SynCardia total artificial heart (TAH) is the only Food and Drug Administration (FDA) approved device for replacing hearts in patients with congestive heart failure. It pumps blood via pneumatically driven diaphragms and controls the flow with mechanical valves. While it has been successfully implanted in more than 1300 patients, its size precludes implantation in smaller patients. This study’s aim was to evaluate the viability of scaled-down TAHs by quantifying thrombogenic potentials from flow patterns. Simulations of systole were first conducted with stationary valves, followed by an advanced full-cardiac cycle model with moving valves. All the models included deforming diaphragms and platelet suspension in the blood flow. Flow stress accumulations were computed for the platelet trajectories and thrombogenic potentials were assessed. The simulations successfully captured complex flow patterns during various phases of the cardiac cycle. Increased stress accumulations, but within the safety margin of acceptable thrombogenicity, were found in smaller TAHs, indicating that they are clinically viable.

AB - The SynCardia total artificial heart (TAH) is the only Food and Drug Administration (FDA) approved device for replacing hearts in patients with congestive heart failure. It pumps blood via pneumatically driven diaphragms and controls the flow with mechanical valves. While it has been successfully implanted in more than 1300 patients, its size precludes implantation in smaller patients. This study’s aim was to evaluate the viability of scaled-down TAHs by quantifying thrombogenic potentials from flow patterns. Simulations of systole were first conducted with stationary valves, followed by an advanced full-cardiac cycle model with moving valves. All the models included deforming diaphragms and platelet suspension in the blood flow. Flow stress accumulations were computed for the platelet trajectories and thrombogenic potentials were assessed. The simulations successfully captured complex flow patterns during various phases of the cardiac cycle. Increased stress accumulations, but within the safety margin of acceptable thrombogenicity, were found in smaller TAHs, indicating that they are clinically viable.

KW - Computational fluid dynamics

KW - Fluid–structure interaction

KW - Mechanical circulatory support devices

KW - Thrombogenic potential

KW - Total artificial heart

UR - http://www.scopus.com/inward/record.url?scp=84911481143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911481143&partnerID=8YFLogxK

U2 - 10.1007/s12265-014-9596-y

DO - 10.1007/s12265-014-9596-y

M3 - Article

C2 - 25354999

AN - SCOPUS:84911481143

VL - 7

SP - 788

EP - 796

JO - Journal of Cardiovascular Translational Research

JF - Journal of Cardiovascular Translational Research

SN - 1937-5387

IS - 9

ER -